Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares Issued
Ratios

Zevra Therapeutics (ZVRA) Accumulated Depreciation & Amortization: 2014-2024

  • Zevra Therapeutics' Accumulated Depreciation & Amortization rose 5.63% to $1.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was $6.7 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $1.7 million for FY2024, which is 5.63% up from last year.
  • According to the latest figures from Q4 2024, Zevra Therapeutics' Accumulated Depreciation & Amortization is $1.7 million, which was up 5.63% from $1.6 million recorded in Q4 2023.
  • In the past 5 years, Zevra Therapeutics' Accumulated Depreciation & Amortization ranged from a high of $1.9 million in Q4 2021 and a low of $1.4 million during Q4 2022.
  • Moreover, its 3-year median value for Accumulated Depreciation & Amortization was $1.6 million (2023), whereas its average is $1.6 million.
  • As far as peak fluctuations go, Zevra Therapeutics' Accumulated Depreciation & Amortization decreased by 25.04% in 2022, and later increased by 13.24% in 2023.
  • Quarterly analysis of 5 years shows Zevra Therapeutics' Accumulated Depreciation & Amortization stood at $1.7 million in 2020, then increased by 11.53% to $1.9 million in 2021, then declined by 25.04% to $1.4 million in 2022, then rose by 13.24% to $1.6 million in 2023, then rose by 5.63% to $1.7 million in 2024.
  • Its Accumulated Depreciation & Amortization was $1.7 million in Q4 2024, compared to $1.6 million in Q4 2023 and $1.4 million in Q4 2022.